Abbott Laboratories (NYSE:ABT) EVP John Landgraf sold 17,293 shares of Abbott Laboratories stock on the open market in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $39.38, for a total value of $680,998.34. Following the completion of the transaction, the executive vice president now directly owns 95,131 shares in the company, valued at approximately $3,746,259. Abbott Laboratories (NYSE:ABT) ended up -0.15% lower to close at $39.73 while trading in the range of $39.73 – $40.23. Its return on asset (ROA) is $7.20 return on investment (ROI) is 8.00%. Abbott Laboratories (NYSE:ABT) monthly performance is 9.60%.

Mylan (NYSE:MYL) Insider Anthony Mauro sold 20,000 shares of the stock on the open market in a transaction dated Monday, March 3rd. The stock was sold at an average price of $54.81, for a total value of $1,096,200.00. Following the completion of the transaction, the insider now directly owns 25,473 shares of the company’s stock, valued at approximately $1,396,175. Mylan Inc. (NASDAQ:MYL) in last trading activity ended up at $54.54 with day range of $53.65 – $56.35. Company weekly performance is -3.07% while its quarterly performance stands at 26.19%. Mylan Inc. (NASDAQ:MYL) is -5.18% away from its 52 week high.

Endo International Plc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism. Testosterone treatments currently include skin patches, short-acting injections and topical gels. AbbVie Inc. (NYSE:ABBV) AndroGel, the market leader, generated about $1.2 billion in sales in 2012. AbbVie Inc. (NYSE:ABBV) belongs to Healthcare sector with market capitalization of 82.85B and has 0.10% insider ownership. In last trading activity company’s stock closed at $52.04 while opening price was $52.04.

Generex Biotechnology Corporation (OTCMKTS:GNBT) on Feb. 27 announced publication of studies examining potential biomarkers associated with overall survival in prostate cancer patients treated with its immunotherapeutic agent AE37. On Thursday shares of Generex Biotechnology Corporation (OTCMKTS:GNBT) opened at $0.04 and closed at $0.0395. This Year Company’s Earnings per Share (EPS) growth is 68.24% and next year’s estimated EPS growth is 18.20%. Analysts mean target price for Generex Biotechnology Corporation (OTCMKTS:GNBT) is $6.00.

Get Free Updates and Stock Alerts!

*We only send one email per week